Nicotinamide adenine dinucleotide (NAD+) sits at the centre of cellular energy metabolism, and its concentration falls in the tissues of ageing model organisms. This article reviews what the primary literature reports about NAD+ biology, why its decline is studied, and what human trials of NAD+ precursors have actually measured — framed strictly for research context.

What NAD+ is, and why cells depend on it

Nicotinamide adenine dinucleotide is one of the most abundant and heavily used small molecules in the cell. In its two interconverting forms, oxidised (NAD+) and reduced (NADH), it acts as an electron carrier for hundreds of redox reactions, shuttling reducing equivalents from the breakdown of glucose, fatty acids and amino acids into the mitochondrial electron transport chain where adenosine triphosphate (ATP) is generated.¹ Without an adequate NAD+/NADH pool, the reactions of glycolysis and the citric acid cycle cannot proceed efficiently, and the cell's capacity to produce ATP is constrained.

Beyond its classical role in redox chemistry, NAD+ is also consumed as a substrate — not merely recycled — by a set of signalling enzymes. According to reviews of NAD+ biology, these include the sirtuin deacylases, the poly(ADP-ribose) polymerases (PARPs) involved in DNA repair, and the CD38/CD157 ectoenzymes.¹² Because these enzymes cleave NAD+ and release nicotinamide, their activity draws down the cellular NAD+ pool, which must then be regenerated. This dual identity — coenzyme and consumable substrate — is what places NAD+ at the intersection of energy metabolism, genome maintenance and cellular stress responses.

The NAD+ economy: made, spent, depleted

Cells maintain their NAD+ level through a balance of synthesis and consumption. Three synthetic routes feed the pool. The salvage pathway recycles nicotinamide released by NAD+-consuming enzymes and is quantitatively the dominant contributor in most tissues. A de novo pathway builds NAD+ from the amino acid tryptophan via the kynurenine pathway, and dietary precursors such as nicotinamide riboside (NR), nicotinamide mononucleotide (NMN) and niacin enter through the Preiss–Handler and salvage routes.¹³ The kynurenine/de novo axis has itself been linked to longevity and mitochondrial function in invertebrate and rodent studies.³

On the consumption side, sirtuins, PARPs and CD38 continually spend NAD+. In young, healthy tissue these flows are balanced. The central observation driving the field is that this balance shifts with age: tissue and cellular NAD+ levels decline gradually across multiple model organisms, including rodents, and this decline has been reported in human tissue as well.¹ Reviews describe the decline as arising from both reduced salvage capacity and increased consumption — a two-sided imbalance rather than a single lesion.¹²

The enzymes that consume NAD+

Understanding why NAD+ matters means looking at what spends it. Three enzyme families dominate.

Sirtuins

The seven mammalian sirtuins (SIRT1–7) are NAD+-dependent deacylases that remove acetyl and related groups from histones and metabolic proteins. Their activity is coupled to NAD+ availability, so they act, in effect, as sensors of the cell's energy state. In rodent and cell studies, SIRT1 and SIRT3 regulate mitochondrial biogenesis and the transcriptional co-activator PGC-1α, linking NAD+ status to the number and function of mitochondria.²⁵ When NAD+ falls, sirtuin activity is constrained.

PARPs and the DNA-damage response

Poly(ADP-ribose) polymerases, principally PARP1, detect DNA breaks and consume large quantities of NAD+ to build poly(ADP-ribose) chains that recruit repair machinery. Work on the base-excision repair pathway describes a coordinated PARP–NAD+–sirtuin axis that governs how repair complexes assemble, making NAD+ bioavailability a limiting factor for genome maintenance.⁴ In neuronal models, sustained PARP1 activation depletes NAD+, suppresses sirtuin-dependent PGC-1α signalling, and impairs mitochondrial respiration — a mechanistic bridge between DNA damage, NAD+ loss and reduced energy output.⁵

CD38 and inflammation

CD38 is an NAD+-degrading ectoenzyme whose expression rises with age and inflammation. In mice, pro-inflammatory macrophages accumulating in metabolic tissues express high levels of CD38 and drive tissue NAD+ decline, and this accumulation is promoted by signals secreted by senescent cells.⁶ This finding reframed part of the age-related NAD+ drop as a consequence of chronic low-grade inflammation rather than metabolism alone — though, again, the causal chain was established in rodent and cell systems.⁶

Why NAD+ decline is linked to fatigue and ageing

The connection researchers draw between NAD+ and fatigue is mechanistic and indirect: because NAD+ is required for the redox reactions that feed ATP synthesis, a lower NAD+ pool is expected to constrain mitochondrial energy output, and mitochondrial dysfunction is a recurring feature of the tissues studied in ageing and metabolic disease.¹³ Reviews describe NAD+ decline as causally linked in model systems to age-associated conditions spanning cognitive decline, metabolic dysfunction and sarcopenia, with restoration of NAD+ slowing or reversing some of these phenotypes in rodents.¹

It is important to keep the altitude honest here. Subjective human fatigue is a complex, multifactorial state, and no primary study establishes that raising NAD+ resolves it. What the literature supports is a well-characterised biochemical requirement for NAD+ in energy metabolism, plus an observed decline with age — not a demonstrated cause-and-effect relationship with everyday tiredness. The related mitochondrial-derived peptide field, including molecules such as MOTS-c, is studied on parallel questions of metabolic regulation, and is similarly early-stage.

What human trials of NAD+ precursors report

Because NAD+ itself is not efficiently taken up intact by cells, most human work has used precursors — chiefly NR and NMN — that the body converts to NAD+. The consistent, reproducible finding across these trials is that oral precursors raise blood NAD+ concentrations and are generally well tolerated over the studied durations. The functional outcomes are where the picture becomes mixed.

Two features of this table deserve emphasis. First, elevating NAD+ is reproducible; translating that into a functional benefit is not uniform — the Remie trial, for example, raised muscle NAD+ metabolites yet found no change in insulin sensitivity or mitochondrial function.⁸ Second, sample sizes are small and durations short. A 2023 review of the human NMN literature concluded plainly that the majority of efficacy evidence still derives from cell and animal models, with human trials limited in size and scope.¹² The honest summary is that NAD+ precursors do what they say biochemically, while their clinical value remains an open research question.

Delivery routes and research considerations

NAD+ and its precursors have been studied across several delivery routes in laboratory and clinical settings, including oral precursors, parenteral NAD+, and direct application to cell and tissue systems in vitro. Each route raises distinct questions about uptake, stability and intracellular conversion — NAD+ is a charged molecule that does not cross membranes freely, which is one reason precursor strategies have dominated human work.¹²

For laboratory investigators, these pharmacological questions define much of the experimental design: dosing of cell cultures, timing of NAD+ measurement, and the choice between adding NAD+ directly versus supplying a precursor for the cell to convert. Purity and batch consistency matter here, because contaminating nicotinamide or degradation products can confound NAD+ quantification and downstream enzyme assays. This is the context in which a defined, characterised research material is used — not as a consumer product.

Working with research-grade NAD+

Fatigue, cognitive change and age-related metabolic shifts are all associated, in the literature, with disruptions in cellular energy pathways — an area of active scientific interest. NAD+ sits at the centre of that interest because of its documented roles in redox metabolism, DNA repair signalling and mitochondrial regulation.¹⁴ Those roles make it a recurring focus for researchers modelling ageing, energy regulation and metabolic stress in vitro.

Qovigen supplies high-purity, research-grade NAD+ (500 mg) for in-vitro and laboratory study only. Batch testing and consistent specification are intended to support reproducible measurement of NAD+-dependent processes — the reproducibility on which the questions above ultimately depend.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.